ImmunologybioRxiv
Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine
K. Modjarrad, Y. Che, W. Chen…·K. Swanson
The monovalent Omicron XBB.1.5-adapted BNT162b2 mRNA vaccine elicits stronger neutralizing antibody responses against XBB.1.5 and related sublineages than the bivalent Wild Type + Omicron BA.4/5 vaccine.
DOI 10.1038/s41541-024-01013-9